Laninamivir
Clinical data | |
---|---|
Routes of administration | Inhalation |
ATC code | |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Laninamivir (CS-8958) is a
Influenzavirus B.[1] It is currently in Phase III clinical trials.[2] It is a long-acting neuraminidase inhibitor administered by nasal inhalation.[3]
Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name Inavir by Daiichi Sankyo. Biota Pharmaceuticals [4] and Daiichi Sankyo co-own Laninamivir. On 1 April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US.[5] It is under clinical evaluations in other countries.[3][6]
References
- PMID 18955520.
- PMID 19067613.
- ^ PMID 23523943.
- ^ "Aviragen Therapeutics - Home". Archived from the original on 2016-04-17. Retrieved 2013-04-12.
- ^ "Biota Pharmaceuticals - Home". Archived from the original on 2016-03-05. Retrieved 2013-04-12.
- S2CID 228892521.